Claire Mazumdar is Chief Executive Officer of Bicara Therapeutics Inc. (BCAX). The company reported total compensation of $927,688 for fiscal year 2025.
| Salary | $625,000 |
|---|---|
| Bonus | $0 |
| Stock awards | $0 |
| Option awards | $0 |
| Non-equity incentive plan | $292,188 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $10,500 |
| Total | $927,688 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Bicara Therapeutics Inc. filed April 27, 2026, accession 0001628280-26-027320.
| Fiscal year | Role | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | Chief Executive Officer | $625,000 | $0 | $0 | $0 | $292,188 | $0 | $10,500 | $927,688 |
| FY2024 | Chief Executive Officer | $517,500 | $287,000 | $0 | $8,088,723 | $10,000 | $0 | $15,300 | $8,918,523 |
Totals as disclosed in each year's own compensation disclosure for Bicara Therapeutics Inc..
| Named executive officer | Role | FY2025 total |
|---|---|---|
| Claire Mazumdar this page | Chief Executive Officer | $927,688 |
| Ryan Cohlhepp | President and Chief Operating Officer | $858,400 |
| David Raben | Chief Medical Officer | $709,164 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Bicara Therapeutics Inc. compensation brief.
Claire Mazumdar's compensation sits inside Bicara Therapeutics Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.